Axsome Therapeutics, Inc. (AXSM) Q2 2018 Earnings Results

Axovant Gene Therapies Misses on EPS, Stock Down 2.86%

Axovant Gene Therapies reported a loss per share of $0.32, but did not provide revenue figures or future guidance. The stock reacted negatively, dropping 2.86%, likely due to the lack of clarity on financial expectations and ongoing clinical developments. Investors may be concerned about the company's path forward without specific targets.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.32	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed a cautious approach regarding future developments. They emphasized the importance of their ongoing clinical trials without providing specific financial guidance.

Management did not provide specific revenue guidance for the upcoming quarters.

The focus remains on advancing their clinical programs.

Axovant Gene Therapies Misses on EPS, Stock Down 2.86%

Key numbers

Management commentary

Axsome Therapeutics, Inc.

More earnings this week

Axovant Gene Therapies Misses on EPS, Stock Down 2.86%

Key numbers

Management commentary